MedTrace Logo

Glycemic Control and Variability for Congestive Heart Failure Exacerbation

NCT00812487 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2013-12-31

Study results available
· View outcomes & findings →

Summary

High glucose as well as fluctuations (rapid swings) in blood glucose can contribute to severe hospital complications and even death.

Conditions

Interventions

DRUG

Intravenous insulin

Patients will receive continuous insulin infusion through the vein.

DRUG

Subcutaneous insulin

4 injections of insulin/day

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Kathleen Dungan

    lead OTHER

Principal Investigators

  • Kathleen M Dungan, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-08-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812487 on ClinicalTrials.gov